Consensus Report on Shigella Controlled Human Infection Model: Immunological Assays

Robert W. Kaminski, Marcela F. Pasetti, Ana Older Aguilar, Kristen A. Clarkson, Sjoerd Rijpkema, A. Louis Bourgeois, Dani Cohen, Ian Feavers, Calman A. MacLennan

Research output: Contribution to journalArticle

Abstract

Moderate to severe diarrhea caused by Shigella is a global health concern due to its substantial contribution to morbidity and mortality in children aged <5 years in low- and middle-income countries. Although antibiotic treatment can be effective, emerging antimicrobial resistance, limited access, and cost affirm the role of vaccines as the most attractive countermeasure. Controlled human infection models (CHIMs) represent a valuable tool for assessing vaccine efficacy and potentially accelerating licensure. Currently, immunological analysis during CHIM studies is customized based on vaccine type, regimen, and administration route. Additionally, differences in type of immunoassays and procedures used limit comparisons across studies. In November 2017, an expert working group reviewed Shigella CHIM studies performed to date and developed consensus guidelines on prioritization of immunoassays, specimens, and collection time points. Immunoassays were ranked into 3 tiers, with antibodies to Shigella lipopolysaccharide (LPS) being the highest priority. To facilitate comparisons across clinical studies, a second workshop was conducted in December 2017, which focused on the pathway toward a recognized enzyme-linked immunosorbent assay (ELISA) to determine serum immunoglobulin G titers against Shigella LPS. The consensus of the meeting was to establish a consortium of international institutions with expertise in Shigella immunology that would work with the National Institute for Biological Standards and Control to establish a harmonized ELISA, produce a reference sera, and identify a reliable source of Shigella LPS for global utilization. Herein we describe efforts toward establishing common procedures to advance Shigella vaccine development, support licensure, and ultimately facilitate vaccine deployment and uptake.

Original languageEnglish (US)
Pages (from-to)S596-S601
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume69
Issue number8
DOIs
StatePublished - Dec 9 2019

Fingerprint

Immunological Models
Shigella
Vaccines
Infection
Immunoassay
Lipopolysaccharides
Licensure
Shigella Vaccines
Enzyme-Linked Immunosorbent Assay
Specimen Handling
Child Mortality
Allergy and Immunology
Serum
Diarrhea
Immunoglobulin G
Guidelines
Anti-Bacterial Agents
Morbidity
Education
Costs and Cost Analysis

Keywords

  • Shigella
  • human infection model
  • immunoassays
  • vaccine

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Consensus Report on Shigella Controlled Human Infection Model : Immunological Assays. / Kaminski, Robert W.; Pasetti, Marcela F.; Aguilar, Ana Older; Clarkson, Kristen A.; Rijpkema, Sjoerd; Bourgeois, A. Louis; Cohen, Dani; Feavers, Ian; MacLennan, Calman A.

In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 69, No. 8, 09.12.2019, p. S596-S601.

Research output: Contribution to journalArticle

Kaminski, Robert W. ; Pasetti, Marcela F. ; Aguilar, Ana Older ; Clarkson, Kristen A. ; Rijpkema, Sjoerd ; Bourgeois, A. Louis ; Cohen, Dani ; Feavers, Ian ; MacLennan, Calman A. / Consensus Report on Shigella Controlled Human Infection Model : Immunological Assays. In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019 ; Vol. 69, No. 8. pp. S596-S601.
@article{9ed3f0e04c74438981691a9dc84ed4bf,
title = "Consensus Report on Shigella Controlled Human Infection Model: Immunological Assays",
abstract = "Moderate to severe diarrhea caused by Shigella is a global health concern due to its substantial contribution to morbidity and mortality in children aged <5 years in low- and middle-income countries. Although antibiotic treatment can be effective, emerging antimicrobial resistance, limited access, and cost affirm the role of vaccines as the most attractive countermeasure. Controlled human infection models (CHIMs) represent a valuable tool for assessing vaccine efficacy and potentially accelerating licensure. Currently, immunological analysis during CHIM studies is customized based on vaccine type, regimen, and administration route. Additionally, differences in type of immunoassays and procedures used limit comparisons across studies. In November 2017, an expert working group reviewed Shigella CHIM studies performed to date and developed consensus guidelines on prioritization of immunoassays, specimens, and collection time points. Immunoassays were ranked into 3 tiers, with antibodies to Shigella lipopolysaccharide (LPS) being the highest priority. To facilitate comparisons across clinical studies, a second workshop was conducted in December 2017, which focused on the pathway toward a recognized enzyme-linked immunosorbent assay (ELISA) to determine serum immunoglobulin G titers against Shigella LPS. The consensus of the meeting was to establish a consortium of international institutions with expertise in Shigella immunology that would work with the National Institute for Biological Standards and Control to establish a harmonized ELISA, produce a reference sera, and identify a reliable source of Shigella LPS for global utilization. Herein we describe efforts toward establishing common procedures to advance Shigella vaccine development, support licensure, and ultimately facilitate vaccine deployment and uptake.",
keywords = "Shigella, human infection model, immunoassays, vaccine",
author = "Kaminski, {Robert W.} and Pasetti, {Marcela F.} and Aguilar, {Ana Older} and Clarkson, {Kristen A.} and Sjoerd Rijpkema and Bourgeois, {A. Louis} and Dani Cohen and Ian Feavers and MacLennan, {Calman A.}",
year = "2019",
month = "12",
day = "9",
doi = "10.1093/cid/ciz909",
language = "English (US)",
volume = "69",
pages = "S596--S601",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Consensus Report on Shigella Controlled Human Infection Model

T2 - Immunological Assays

AU - Kaminski, Robert W.

AU - Pasetti, Marcela F.

AU - Aguilar, Ana Older

AU - Clarkson, Kristen A.

AU - Rijpkema, Sjoerd

AU - Bourgeois, A. Louis

AU - Cohen, Dani

AU - Feavers, Ian

AU - MacLennan, Calman A.

PY - 2019/12/9

Y1 - 2019/12/9

N2 - Moderate to severe diarrhea caused by Shigella is a global health concern due to its substantial contribution to morbidity and mortality in children aged <5 years in low- and middle-income countries. Although antibiotic treatment can be effective, emerging antimicrobial resistance, limited access, and cost affirm the role of vaccines as the most attractive countermeasure. Controlled human infection models (CHIMs) represent a valuable tool for assessing vaccine efficacy and potentially accelerating licensure. Currently, immunological analysis during CHIM studies is customized based on vaccine type, regimen, and administration route. Additionally, differences in type of immunoassays and procedures used limit comparisons across studies. In November 2017, an expert working group reviewed Shigella CHIM studies performed to date and developed consensus guidelines on prioritization of immunoassays, specimens, and collection time points. Immunoassays were ranked into 3 tiers, with antibodies to Shigella lipopolysaccharide (LPS) being the highest priority. To facilitate comparisons across clinical studies, a second workshop was conducted in December 2017, which focused on the pathway toward a recognized enzyme-linked immunosorbent assay (ELISA) to determine serum immunoglobulin G titers against Shigella LPS. The consensus of the meeting was to establish a consortium of international institutions with expertise in Shigella immunology that would work with the National Institute for Biological Standards and Control to establish a harmonized ELISA, produce a reference sera, and identify a reliable source of Shigella LPS for global utilization. Herein we describe efforts toward establishing common procedures to advance Shigella vaccine development, support licensure, and ultimately facilitate vaccine deployment and uptake.

AB - Moderate to severe diarrhea caused by Shigella is a global health concern due to its substantial contribution to morbidity and mortality in children aged <5 years in low- and middle-income countries. Although antibiotic treatment can be effective, emerging antimicrobial resistance, limited access, and cost affirm the role of vaccines as the most attractive countermeasure. Controlled human infection models (CHIMs) represent a valuable tool for assessing vaccine efficacy and potentially accelerating licensure. Currently, immunological analysis during CHIM studies is customized based on vaccine type, regimen, and administration route. Additionally, differences in type of immunoassays and procedures used limit comparisons across studies. In November 2017, an expert working group reviewed Shigella CHIM studies performed to date and developed consensus guidelines on prioritization of immunoassays, specimens, and collection time points. Immunoassays were ranked into 3 tiers, with antibodies to Shigella lipopolysaccharide (LPS) being the highest priority. To facilitate comparisons across clinical studies, a second workshop was conducted in December 2017, which focused on the pathway toward a recognized enzyme-linked immunosorbent assay (ELISA) to determine serum immunoglobulin G titers against Shigella LPS. The consensus of the meeting was to establish a consortium of international institutions with expertise in Shigella immunology that would work with the National Institute for Biological Standards and Control to establish a harmonized ELISA, produce a reference sera, and identify a reliable source of Shigella LPS for global utilization. Herein we describe efforts toward establishing common procedures to advance Shigella vaccine development, support licensure, and ultimately facilitate vaccine deployment and uptake.

KW - Shigella

KW - human infection model

KW - immunoassays

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85076299283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076299283&partnerID=8YFLogxK

U2 - 10.1093/cid/ciz909

DO - 10.1093/cid/ciz909

M3 - Article

C2 - 31816067

AN - SCOPUS:85076299283

VL - 69

SP - S596-S601

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 8

ER -